findmyKOL
Clinical trialNCT00004101CompletedPhase 1Interventional

Monoclonal Antibody Therapy in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

SponsorNational Cancer Institute (NCI)Enrollment35Lymphoma
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Walter Reed Army Medical Center

    Washington D.C., District of Columbia, United States

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa, United States

  • Johns Hopkins Oncology Center

    Baltimore, Maryland, United States

  • Biologics Evaluation Section

    Bethesda, Maryland, United States

  • New York Presbyterian Hospital - Cornell Campus

    New York, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Nov 1999
Primary completion
30 Jun 2005
Completion
Last update posted
11 Feb 2013
Registered enrollment
35
Registry id
NCT00004101

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.